Colin Dayan

Colin Dayan, MA MBBS, FRCP, PhD – biographical details. Professor of Clinical Diabetes and Metabolism, Cardiff University School of Medicine. Senior Clinical Researcher, University of Oxford. Director, Cardiff Joint Research Office. Colin Dayan trained in medicine at University College, Oxford, and Guy’s and Charing Cross Hospitals in London, UK before obtaining a PhD in the immunology of Graves’ Disease in the Laboratory of Sir Marc Feldmann. He then spent a year as an endocrine fellow at the Massachussetts General Hospital in Boston, USA before completing his specialist training in diabetes and endocrinology as a Lecturer in Bristol. In 2010, he was appointed to the Chair of Clinical Diabetes and Metabolism at Cardiff University School of Medicine and in 2020 as part-time Senior Clinical Researcher in the Nuffield Department of Medicine at the University of Oxford. In 2021 he became Director of the Cardiff Joint Research Office overseeing clinical research in Cardiff University and Cardiff and Vale University Health Board. He is currently Clinical Research Secretary of the British Society for Immunology. Prof Dayan has a long established interest in translational research in the immunopathology of type 1 diabetes and is currently conducting early phase clinical trials in the development of antigen specific immunotherapy as well as leading multicentre phase 2 studies. He leads the T1D-Plus adaptive platform trial, ,which is testing combination therapies in beta cell preservation across the UK, Europe and Australia. His clinical interests in diabetes include management of poor compliance in type 1 diabetes and models of community care in diabetes. He represents Wales in the National Diabetes Audit research advisory panel and leads an all Wales anonymised data linkage programme for monitoring childhood type 1 diabetes. He has been part of 4 major EU programme grants in type 1 diabetes (and coordinator on one) and an advisor to the Juvenile Diabetes Research Foundation. Prof Dayan leads the Clinical Trials Core of the UK Type 1 Diabetes Research Consortium (UKT1D-RC) which collaborates closely with the INNODIA European network and aims to support combined efforts to bring immunotherapy and beta cell preservation for type 1 diabetes into clinical practice. He also chairs the UK Clinical Studies Group for prevention, targets and therapies in type 1 diabetes.